Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TELA Bio, Inc.TELA · Entity 7381 | Chief Financial Officer | March 31, 2021 | April 02, 2021 |
| Traws Pharma, Inc.TRAW · Entity 8032 | Interim CFO | February 05, 2025 | February 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TELA Bio, Inc.
Report date March 31, 2021 · Filed April 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,696 |
Reported balance
After 2021-03-31 transaction · row 1
1 source rowRow 1 · 2021-03-31 · Grant · Acquired 2,928 · Balance 17,696 F1: These restricted stock units will vest in four equal annual installments beginning on March 31, 2022, subject to the Reporting Person's continuous service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units will vest in four equal annual installments beginning on March 31, 2022, subject to the Reporting Person's continuous service with the Issuer.
Traws Pharma, Inc.
Report date February 05, 2025 · Filed February 08, 2025
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SPECTRUM PHARMACEUTICALS INC
Report date July 31, 2023 · Filed August 01, 2023
Section 16 reporting ended · disclosed 2023-08-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-31 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-07-31 · Disposition to issuer · Disposed 104,823 · Balance 0 F1: Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation ("Acquiror"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the "Upfront Consideration") and (b) a contingent value right ("CVR") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the "Merger Consideration") on the effective date of the merger. |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-31 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-07-31 · Disposition to issuer · Disposed 463,005 · Balance 0 F2: Represents shares underlying restricted stock units of the Issuer, which were disposed of pursuant to the Merger Agreement in exchange for the aggregate Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 | Direct | 0 |
Reported balance
After 2023-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-31 · Disposition to issuer · Disposed 840,000 · Balance 0 F3: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F4: (Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 | Direct | 0 |
Reported balance
After 2023-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-07-31 · Disposition to issuer · Disposed 1,515,957 · Balance 0 F3: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F4: (Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation ("Acquiror"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the "Upfront Consideration") and (b) a contingent value right ("CVR") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the "Merger Consideration") on the effective date of the merger.
F2: Represents shares underlying restricted stock units of the Issuer, which were disposed of pursuant to the Merger Agreement in exchange for the aggregate Merger Consideration.
F3: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,
F4: (Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2023 Filed Aug 1, 2023 17:11 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,515,957 | Not disclosed Strike: $0.71 | Not disclosed |
DisclosureSEC source: 0000899243-23-017673 · doc4.xml · derivative · entry 4 Brennan Nora · CIK 0001790215 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,515,957 shares Expires not disclosed F3 · price: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F4 · price: (Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. F3 · derivative.exercise_date: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F4 · derivative.exercise_date: (Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. F3 · derivative.expiration_date: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F4 · derivative.expiration_date: (Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 17:11 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | Disposition to issuerStock Option (Right to Buy) · Derivative | 840,000 | Not disclosed Strike: $0.38 | Not disclosed |
DisclosureSEC source: 0000899243-23-017673 · doc4.xml · derivative · entry 3 Brennan Nora · CIK 0001790215 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 840,000 shares Expires not disclosed F3 · price: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F4 · price: (Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. F3 · derivative.exercise_date: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F4 · derivative.exercise_date: (Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. F3 · derivative.expiration_date: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F4 · derivative.expiration_date: (Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 17:11 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | Disposition to issuerCommon Stock, $0.001 par value | 463,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-017673 · doc4.xml · nonDerivative · entry 2 Brennan Nora · CIK 0001790215 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: Represents shares underlying restricted stock units of the Issuer, which were disposed of pursuant to the Merger Agreement in exchange for the aggregate Merger Consideration. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 17:11 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | Disposition to issuerCommon Stock, $0.001 par value | 104,823 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-017673 · doc4.xml · nonDerivative · entry 1 Brennan Nora · CIK 0001790215 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation ("Acquiror"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the "Upfront Consideration") and (b) a contingent value right ("CVR") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the "Merger Consideration") on the effective date of the merger. Read SEC document |
| May 26, 2023 Filed May 30, 2023 19:36 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 32,387 | $1.10 | $35,496.15 |
DisclosureSEC source: 0000950170-23-025014 · ownership.xml · nonDerivative · entry 1 Brennan Nora · CIK 0001790215 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 567,828 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 19:49 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantStock Option (Right to Buy) · Derivative | 840,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0000899243-23-001064 · doc4.xml · derivative · entry 2 Brennan Nora · CIK 0001790215 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840,000 Underlying: Common Stock · 840,000 shares Expires 2033-01-03 F2 · derivative.exercise_date: One third of the aggregate amount of option shares shall vest on each of January 3, 2024, 2025 and 2026, respectively. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 19:49 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001064 · doc4.xml · nonDerivative · entry 1 Brennan Nora · CIK 0001790215 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,215 F1 · shares: One third of the aggregate amount of restricted stock units shall vest on each of January 3, 2024, 2025 and 2026, respectively. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 19:56 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantStock Option (Right to Buy) · Derivative | 1,515,957 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001209191-22-039057 · doc4.xml · derivative · entry 3 Brennan Nora · CIK 0001790215 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,515,957 Underlying: Common Stock · 1,515,957 shares Expires 2032-05-25 F3 · date: The option grant was approved by Spectrum's board of directors on May 25, 2022, subject to stockholder approval of the Plan under which the option was granted. Spectrum's stockholders approved the Plan on June 21, 2022. F4 · derivative.exercise_date: One third of the aggregate amount of option shares shall vest on each of May 25, 2023, 2024 and 2025, respectively. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 19:56 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | SaleCommon Stock, $0.001 par value | 3,569 | $0.79 | $2,801.67 |
DisclosureSEC source: 0001209191-22-039057 · doc4.xml · nonDerivative · entry 2 Brennan Nora · CIK 0001790215 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,215 F2 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 19:56 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 334,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039057 · doc4.xml · nonDerivative · entry 1 Brennan Nora · CIK 0001790215 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,784 F1 · date: The restricted stock unit grant was approved by Spectrum Pharmaceuticals, Inc's ("Spectrum") board of directors on May 25, 2022, subject to stockholder approval of the Amended and Restated 2018 Long-Term Incentive Plan (the "Plan") under which the restricted stock unit was granted. Spectrum's stockholders approved the Plan on June 21, 2022. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 18:35 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantStock Option (Right to Buy) · Derivative | 67,804 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001209191-21-042511 · doc4.xml · derivative · entry 2 Brennan Nora · CIK 0001790215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,804 Underlying: Common Stock · 67,804 shares Expires 2031-06-17 F2 · derivative.exercise_date: One third of the aggregate amount of option shares shall vest on each of June 17, 2022, 2023 and 2024, respectively. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 18:35 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 14,277 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-042511 · doc4.xml · nonDerivative · entry 1 Brennan Nora · CIK 0001790215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,277 F1 · shares: 100% of the restricted shares shall vest on the earlier of (1) June 17, 2022 or (2) the date of the company's 2022 Annual Meeting of Stockholders. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 18:41 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 2,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000297 · edgar.xml · nonDerivative · entry 1 Brennan Nora · CIK 0001790215 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,696 F1 · shares: These restricted stock units will vest in four equal annual installments beginning on March 31, 2022, subject to the Reporting Person's continuous service with the Issuer. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:25 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (right to buy) · Derivative | 20,100 | $0.00 Strike: $16.99 | $0.00 |
DisclosureSEC source: 0001192482-21-000189 · edgar.xml · derivative · entry 2 Brennan Nora · CIK 0001790215 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2031-02-24 F2 · derivative.exercise_date: The option vests 25% on February 24, 2022, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continuous service with the Issuer. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:25 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 11,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000189 · edgar.xml · nonDerivative · entry 1 Brennan Nora · CIK 0001790215 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,768 F1 · shares: These restricted stock units will vest in four equal annual installments beginning on February 24, 2022, subject to the Reporting Person's continuous service with the Issuer. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 16:05 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.69 | $0.00 |
DisclosureSEC source: 0001209191-20-063198 · doc4.xml · derivative · entry 2 Brennan Nora · CIK 0001790215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-12-10 F2 · derivative.exercise_date: One third of the aggregate amount of option shares shall vest on each of December 10, 2021, 2022 and 2023, respectively. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 16:05 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-063198 · doc4.xml · nonDerivative · entry 1 Brennan Nora · CIK 0001790215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: 100% of the restricted shares shall vest on June 17, 2021. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries B Preferred Stock · Derivative | 86,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000425 · edgar.xml · derivative · entry 2 Brennan Nora · CIK 0001790215 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,491 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F2 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:52 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 3,491 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000425 · edgar.xml · nonDerivative · entry 1 Brennan Nora · CIK 0001790215 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F2 · balance_after: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. F3 · balance_after: Reflects 177 shares of common stock received by the reporting person as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.